Nephros Inc (NASDAQ: NEPH)

Nephros is a commercial stage company that develops and markets water filtration solutions for point of use applications with a core focus on medical grade water filtration. The company designs manufactures and sells filters that remove bacteria viruses endotoxins particulates and chemical contaminants from water at the point where it is used. Its products serve healthcare settings such as hospitals and dialysis centers as well as commercial environments including foodservice hospitality laboratories manufacturing aviation and government facilities. Nephros was incorporated in Delaware in April 1997 and maintains headquarters in South Orange New Jersey. The firm emphasizes innovation in membrane technology to meet stringent safety and performance requirements in critical water applications.

Nephros generates revenue primarily through the sale of its filtration products to end users via a network of value added resellers and a direct sales force. The company sells medical grade infection control and dialysis filters mainly through distributors that also serve broader commercial markets. Commercial filters are sold both directly to customers and through selected distributor partnerships. Revenue is derived from product sales and from recurring replacement filter cartridges that ensure ongoing performance and compliance. In addition Nephros earns income from licensing agreements and supply arrangements that provide access to proprietary membrane technologies while securing long term purchase commitments.

The company operates through the following segments: Infection Control, Dialysis, and Commercial.

• The Infection Control segment includes microfilters with a 0.1 micron pore size that retain bacteria and ultrafilters with a 0.005 micron pore size that retain bacteria viruses and endotoxins. These filters are FDA 510(k) cleared as Class II medical devices and are used at sinks showers ice machines and sterile processing areas to prevent waterborne pathogen transmission. The segment serves hospitals outpatient clinics and other healthcare facilities where infection risk is a concern. Nephros highlights the long service life and high membrane surface area of its filters which reduce the frequency of filter changes and support continuous protection in high demand environments.

• The Dialysis segment provides ultrafilters that are installed in water treatment loops upstream of dialysis machines or after reverse osmosis systems to purify water and bicarbonate concentrate used in hemodialysis. These ultrafilters also have a 0.005 micron pore size and retain bacteria viruses and endotoxins. They are FDA 510(k) cleared Class II medical devices and support the achievement of ultrapure dialysate quality required for safe patient treatment. The segment benefits from the critical need for endotoxin control in dialysis water where even low levels can provoke inflammatory reactions in patients undergoing treatment.

• The Commercial segment offers carbon based and carbon free filters that improve taste and odor reduce scale buildup remove cysts particulates lead and emerging contaminants such as Total PFAS. These products are used in foodservice hospitality laboratories manufacturing aviation and government buildings where water quality affects equipment performance and consumer satisfaction. The segment also includes filters that provide a barrier against microbiological contaminants when paired with medical grade products. Nephros markets its commercial solutions as a way to extend the lifespan of water using equipment lower maintenance costs and meet emerging regulatory standards for contaminants such as PFAS.

Nephros competes in the medical filtration space against established players such as Cytiva formerly Pall Corporation Aquatools Aquamedix and i3 and in the commercial water filtration arena against 3M Company and Pentair. The company differentiates itself through FDA 510(k) cleared status validated performance reliability and ease of use in mission critical environments. Its filters feature one of the smallest pore sizes available providing superior retention of viruses and endotoxins compared with many competitors. Additionally Nephros emphasizes long service life and broad membrane surface area which reduce replacement frequency and lower total cost of ownership. The firm leverages its distributor network and direct sales force to educate customers on regulatory requirements and risk based filtration selection further strengthening its market position. Intellectual property protection through patents and trademarks also contributes to its competitive edge by safeguarding core technologies and brand identity.

The company serves a diverse customer base that includes hospitals dialysis clinics foodservice and hospitality operations laboratories manufacturing facilities aviation companies and government agencies. While specific customer names are not disclosed in the filing the company reports that a small group of major customers accounted for a significant portion of revenues in recent years. The broad applicability of its filtration solutions allows Nephros to address water safety needs across multiple regulated and non regulated sectors. In healthcare the firm supplies infection control filters to large hospital systems and dialysis providers while in foodservice it supports quick service restaurants hotels and convenience stores. In industrial settings its filters protect manufacturing processes and laboratory instruments from particulate and microbial contamination.